These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 19366800)

  • 1. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas.
    Szeto MD; Chakraborty G; Hadley J; Rockne R; Muzi M; Alvord EC; Krohn KA; Spence AM; Swanson KR
    Cancer Res; 2009 May; 69(10):4502-9. PubMed ID: 19366800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma.
    Kawai N; Maeda Y; Kudomi N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T
    Eur J Nucl Med Mol Imaging; 2011 Mar; 38(3):441-50. PubMed ID: 21072512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas.
    Swanson KR; Chakraborty G; Wang CH; Rockne R; Harpold HL; Muzi M; Adamsen TC; Krohn KA; Spence AM
    J Nucl Med; 2009 Jan; 50(1):36-44. PubMed ID: 19091885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applying a patient-specific bio-mathematical model of glioma growth to develop virtual [18F]-FMISO-PET images.
    Gu S; Chakraborty G; Champley K; Alessio AM; Claridge J; Rockne R; Muzi M; Krohn KA; Spence AM; Alvord EC; Anderson AR; Kinahan PE; Swanson KR
    Math Med Biol; 2012 Mar; 29(1):31-48. PubMed ID: 21562060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI,
    Collet S; Guillamo JS; Berro DH; Chakhoyan A; Constans JM; Lechapt-Zalcman E; Derlon JM; Hatt M; Visvikis D; Guillouet S; Perrio C; Bernaudin M; Valable S
    J Nucl Med; 2021 Oct; 62(10):1349-1356. PubMed ID: 34016725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ¹⁸F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas.
    Hirata K; Terasaka S; Shiga T; Hattori N; Magota K; Kobayashi H; Yamaguchi S; Houkin K; Tanaka S; Kuge Y; Tamaki N
    Eur J Nucl Med Mol Imaging; 2012 May; 39(5):760-70. PubMed ID: 22307533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.
    Toyonaga T; Yamaguchi S; Hirata K; Kobayashi K; Manabe O; Watanabe S; Terasaka S; Kobayashi H; Hattori N; Shiga T; Kuge Y; Tanaka S; Ito YM; Tamaki N
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):611-619. PubMed ID: 27752745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vivo Relationship Between Hypoxia and Angiogenesis in Human Glioblastoma: A Multimodal Imaging Study.
    Ponte KF; Berro DH; Collet S; Constans JM; Emery E; Valable S; Guillamo JS
    J Nucl Med; 2017 Oct; 58(10):1574-1579. PubMed ID: 28596159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and
    Huang S; Michalek JE; Reardon DA; Wen PY; Floyd JR; Fox PT; Clarke GD; Jerabek PA; Schmainda KM; Muzi M; Hyun H; Lee EQ; Brenner AJ
    Sci Rep; 2021 Apr; 11(1):7632. PubMed ID: 33828310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of hypoxia in human glioblastoma tumors with dynamic 18F-FMISO PET imaging.
    Abdo RA; Lamare F; Fernandez P; Bentourkia M
    Australas Phys Eng Sci Med; 2019 Dec; 42(4):981-993. PubMed ID: 31520369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model.
    Wang CH; Rockhill JK; Mrugala M; Peacock DL; Lai A; Jusenius K; Wardlaw JM; Cloughesy T; Spence AM; Rockne R; Alvord EC; Swanson KR
    Cancer Res; 2009 Dec; 69(23):9133-40. PubMed ID: 19934335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing hypoxia in human glioma: A simultaneous multimodal MRI and PET study.
    Preibisch C; Shi K; Kluge A; Lukas M; Wiestler B; Göttler J; Gempt J; Ringel F; Al Jaberi M; Schlegel J; Meyer B; Zimmer C; Pyka T; Förster S
    NMR Biomed; 2017 Nov; 30(11):. PubMed ID: 28805936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.
    Kosztyla R; Chan EK; Hsu F; Wilson D; Ma R; Cheung A; Zhang S; Moiseenko V; Benard F; Nichol A
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1100-6. PubMed ID: 24161427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using 18F-FMISO-PET.
    Rockne RC; Trister AD; Jacobs J; Hawkins-Daarud AJ; Neal ML; Hendrickson K; Mrugala MM; Rockhill JK; Kinahan P; Krohn KA; Swanson KR
    J R Soc Interface; 2015 Feb; 12(103):. PubMed ID: 25540239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis.
    Bekaert L; Valable S; Lechapt-Zalcman E; Ponte K; Collet S; Constans JM; Levallet G; Bordji K; Petit E; Branger P; Emery E; Manrique A; Barré L; Bernaudin M; Guillamo JS
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1383-1392. PubMed ID: 28315948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O.
    Bruehlmeier M; Roelcke U; Schubiger PA; Ametamey SM
    J Nucl Med; 2004 Nov; 45(11):1851-9. PubMed ID: 15534054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical Decision Making From Image-Based Biophysical Modeling of Glioblastoma: Not Ready for Primetime.
    Amelot A; Deroulers C; Badoual M; Polivka M; Adle-Biassette H; Houdart E; Carpentier AF; Froelich S; Mandonnet E
    Neurosurgery; 2017 May; 80(5):793-799. PubMed ID: 28387870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.
    Hayes AR; Jayamanne D; Hsiao E; Schembri GP; Bailey DL; Roach PJ; Khasraw M; Newey A; Wheeler HR; Back M
    Pract Radiat Oncol; 2018; 8(4):230-238. PubMed ID: 29730279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying G6PC3 as a Potential Key Molecule in Hypoxic Glucose Metabolism of Glioblastoma Derived from the Depiction of
    Okamoto M; Yamaguchi S; Sawaya R; Echizenya S; Ishi Y; Kaneko S; Motegi H; Toyonaga T; Hirata K; Fujimura M
    Biomed Res Int; 2024; 2024():2973407. PubMed ID: 38449509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of [11C]methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning.
    Matsuo M; Miwa K; Tanaka O; Shinoda J; Nishibori H; Tsuge Y; Yano H; Iwama T; Hayashi S; Hoshi H; Yamada J; Kanematsu M; Aoyama H
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):83-9. PubMed ID: 21095072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.